BLAINTRAVENOUSVIALPriority Review
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
REMICADE (infliximab) by Samsung Bioepis is tumor necrosis factor receptor blocking activity [moa]. Approved for rheumatoid arthritis, crohn's disease, ulcerative colitis and 3 more indications. First approved in 1998.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REMICADE (infliximab) is a monoclonal antibody TNF blocker administered intravenously, approved by the FDA in August 1998. It works by blocking tumor necrosis factor receptor activity to reduce inflammatory responses. The drug is indicated for multiple autoimmune and inflammatory conditions and remains a foundational biologic therapy in the immunology treatment landscape.
$0.1BPart D
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (6)
Worked on REMICADE at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.